Prognostic biomarkers in diffuse large B-cell lymphoma

Izidore S. Lossos, Daniel Morgensztern

Research output: Contribution to journalReview articlepeer-review

220 Scopus citations


Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin's lymphoma. Although it represents a curable disease, less than half of the patients are cured with conventional chemotherapy. The highly variable outcome reflects a heterogeneous group of tumors, with different genetic abnormalities and response to therapy. The International Prognostic Index (IPI) is useful in predicting the outcome of DLBCL patients. However, patients with identical IPI still exhibit marked variability in survival, suggesting the presence of significant residual heterogeneity within each IPI category. The discovery of specific genetic alterations and the assessment of protein expression led to the identification of multiple novel single molecular markers capable of predicting the outcome of DLBCL patients independently of clinical variables. The recent application of DNA microarrays and tissue array technologies allowed a better understanding of the biology of lymphoma and the development of novel diagnostic tools capable of improving the current models for outcome prediction. However, much confusion exists in the literature regarding the importance of different prognostic biomarkers and their applicability in routine practice. This review summarizes the recent advances in our understanding of prognostic biomarkers in DLBCL and discusses whether this is the right time for biomarkers-guided risk-adjusted therapy.

Original languageEnglish
Pages (from-to)995-1007
Number of pages13
JournalJournal of Clinical Oncology
Issue number6
StatePublished - Feb 20 2006


Dive into the research topics of 'Prognostic biomarkers in diffuse large B-cell lymphoma'. Together they form a unique fingerprint.

Cite this